| Literature DB >> 32331512 |
Yan-Jia Hu1, Yue-Bing Xie1, Li-Feng Zhang1, Chang Ding1, Jing Chen2.
Abstract
BACKGROUND: Parasellar meningioma is a common benign tumour in brain. Both surgery and radiosurgery are important treatment modalities for this tumour. The study was designed to investigate whether prior surgery would affect treatment outcomes of patients with parasellar meningiomas after management with Gamma Knife radiosurgery.Entities:
Keywords: Cavernous sinus; Clinical outcomes; Gamma knife radiosurgery; Parasellar meningiomas; Surgery
Mesh:
Year: 2020 PMID: 32331512 PMCID: PMC7183119 DOI: 10.1186/s12883-020-01731-2
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Baseline characteristics of patients
| Characteristics | Value |
|---|---|
| Sex | |
| Male | 30 (32.3%) |
| Female | 63 (67.7%) |
| Patients with prior surgery | 45 (48.4%) |
| Median Age (range), yr | 48.6 (15.2–78.7) |
| Median Tumor volume (range), cm3 | 5.02 (1.07–35.46) |
| Indication for GKRS | |
| Primary | 48 (51.6%) |
| Residual | 31 (33.3%) |
| Recurrent | 14 (15.1%) |
| Median time interval between surgery and GKRS (range), month | |
| For all patients | 5.1 (0.17–300) |
| For recurrent patients | 33.6 (3.8–300) |
| For patients with residual tumor | 3.8 (0.17–12) |
| GKRS parameters | |
| Median margin dose (range), Gy | 12 (10–15) |
| Mean margin dose, Gy | 12.2 |
| Median maximum dose (range), Gy | 25 (20–33.3) |
| Mean maximum dose, Gy | 25.8 |
| Median isodose line (range) | 47% (43–50%) |
| Mean imaging follow-up in months (range) | 40.7 (6–119.4) |
| Mean clinical follow-up in months (range) | 52.7 (9.6–123.4) |
Abbreviations: yr year; GKRS Gamma Knife radiosurgery
Comparison of patient demographic between two groups
| Variables | Patients with prior surgery | Patients without prior surgery | |
|---|---|---|---|
| Age (range), yr | 48.1 (15.2–71) | 55.2 (16.6–78.7) | 0.004* |
| Follow-up, mo | 47.0 (6.6–111.6) | 34.8 (6–119.4) | 0.037* |
| Tumor volume, cm3 | 8.77 (1.07–29.76) | 7.78 (1.15–35.46) | 0.500 |
| Margin dose, Gy | 12.2 (10–15) | 12.3 (10–15) | 0.681 |
| Maximum dose, Gy | 25.7 (20–31.1) | 25.8 (22–33.3) | 0.749 |
| With symptoms, no. (%) | 42 (93.3%) | 41(85.4%) | 0.319 |
Abbreviations: yr years, mo month, no. number; *, statistical significance. Continuous variables are described as means and ranges and categorical variables are described as numbers
Symptoms of each groups at the time of Gamma Knife Radiosurgery
| Symptoms | With prior surgery | Without prior surgery |
|---|---|---|
| Headache | 11 | 18 |
| Facial numbness | 5 | 11 |
| Hearing loss | 3 | 0 |
| Ptosis | 4 | 4 |
| Ocular motility disorders | 5 | 3 |
| Visual field defect | 5 | 3 |
| Diplopia | 2 | 5 |
| Dizziness | 1 | 0 |
| Facial pain | 0 | 4 |
| Tinnitus | 1 | 0 |
| Facial paresthesia | 2 | 2 |
| Exophthalmos | 1 | 2 |
| Extremity numbness | 0 | 3 |
| Seizure | 3 | 0 |
| Facial paresis | 2 | 0 |
Changes of preexisting symptoms and the new-onset symptoms at the latest follow-up
| With prior surgery ( | Without prior surgery ( | ||
|---|---|---|---|
| Patients with symptoms | 42 | 41 | 0.319 |
| Improved | 20 (47.6%) | 31 (75.6%) | 0.009 |
| Unchanged | 10 (23.8%) | 3 (7.3%) | 0.012 |
| Worse | 12 (28.5%) | 7 (17.1%) | 0.213 |
| New-onset symptoms | 6 (13.3%) | 4 (8.3%) | 0.515 |
GKRS Gamma Knife radiosurgery. When we calculated the percentages of changes of preexisting symptoms, the number of patients with symptoms was used as denominator. Number of all patients was used as denominator when we calculated the percentages of new-onset symptoms in two groups
Fig. 1Kaplan-Meier analysis of progression-free survival after Gamma Knife radiosurgery (GKRS). The tumor control rate at 3, 5, 7 years after GKRS were 94.8, 90.4, and 73.6%, respectively
Fig. 2Kaplan-Meier analysis of progression-free survival after Gamma Knife radiosurgery (GKRS) regarding surgery prior to GKRS. Log-rank test showed no difference of PFS between two groups (P = 0.229)